D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 80 Citations 37,840 255 World Ranking 9807 National Ranking 5250

Overview

What is she best known for?

The fields of study she is best known for:

  • Cancer
  • Internal medicine
  • Chemotherapy

Kathy S. Albain mainly investigates Internal medicine, Oncology, Breast cancer, Surgery and Chemotherapy. All of her Internal medicine and Lung cancer, Cancer, Randomized controlled trial, Performance status and Clinical endpoint investigations are sub-components of the entire Internal medicine study. Her Oncology research includes themes of Metastatic breast cancer, Proportional hazards model, Hazard ratio and Chemoradiotherapy, Radiation therapy.

Her Breast cancer research is multidisciplinary, relying on both Biomarker, Gynecology and Adjuvant therapy. The concepts of her Surgery study are interwoven with issues in Placebo, Metastasis, Trastuzumab and Intensive care medicine. Her Chemotherapy research incorporates elements of Bone pain, Bisphosphonate and Osteolysis.

Her most cited work include:

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial (2280 citations)
  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (1828 citations)
  • Underrepresentation of patients 65 years of age or older in cancer-treatment trials. (1770 citations)

What are the main themes of her work throughout her whole career to date?

Kathy S. Albain focuses on Internal medicine, Oncology, Breast cancer, Chemotherapy and Cancer. Her research ties Surgery and Internal medicine together. Her study on Oncology also encompasses disciplines like

  • Radiation therapy which intersects with area such as Disease,
  • Docetaxel, which have a strong connection to Gefitinib.

Her Breast cancer research focuses on subjects like Hazard ratio, which are linked to Proportional hazards model. Her research integrates issues of Taxane and Anthracycline in her study of Chemotherapy. Her biological study deals with issues like Cancer research, which deal with fields such as Notch signaling pathway.

She most often published in these fields:

  • Internal medicine (77.07%)
  • Oncology (63.38%)
  • Breast cancer (55.10%)

What were the highlights of her more recent work (between 2018-2021)?

  • Internal medicine (77.07%)
  • Breast cancer (55.10%)
  • Oncology (63.38%)

In recent papers she was focusing on the following fields of study:

Her primary areas of study are Internal medicine, Breast cancer, Oncology, Chemotherapy and Cancer. The Internal medicine study which covers MEDLINE that intersects with Cooperative group and Anastrozole. The various areas that Kathy S. Albain examines in her Breast cancer study include Hazard ratio, Clinical trial, Proportional hazards model and Chemotherapy regimen.

Her Oncology study combines topics in areas such as Adjuvant chemotherapy, MammaPrint, Clinical endpoint and Trastuzumab. She has included themes like Receptor, Tamoxifen, Adverse effect and Hormone receptor in her Chemotherapy study. Her Cancer study integrates concerns from other disciplines, such as High risk patients and Therapeutic regimen.

Between 2018 and 2021, her most popular works were:

  • Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer (118 citations)
  • Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial (90 citations)
  • Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (75 citations)

In her most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Chemotherapy

Her scientific interests lie mostly in Internal medicine, Breast cancer, Oncology, Chemotherapy and Randomized controlled trial. Her studies in Breast cancer integrate themes in fields like Hazard ratio, Prospective cohort study, Chemotherapy regimen and Clinical trial. Her studies deal with areas such as Physical fitness, Cancer, Adjuvant therapy, Confidence interval and Tamoxifen as well as Prospective cohort study.

Her Oncology research integrates issues from Taxane, Clinical endpoint and Docetaxel. Her Chemotherapy research is multidisciplinary, incorporating perspectives in Adjuvant, Receptor, Disease and Anthracycline. The various areas that Kathy S. Albain examines in her Randomized controlled trial study include Progression-free survival, Proportional hazards model and MEDLINE.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial

Mark G. Kris;Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Thomas J. Lynch.
JAMA (2003)

3263 Citations

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)

2956 Citations

Underrepresentation of patients 65 years of age or older in cancer-treatment trials.

Laura F. Hutchins;Joseph M. Unger;John J. Crowley;Charles A. Coltman.
The New England Journal of Medicine (1999)

2283 Citations

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi.
Lancet Oncology (2010)

1610 Citations

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

Kathy S Albain;R Suzanne Swann;Valerie W Rusch;Andrew T Turrisi.
The Lancet (2009)

1336 Citations

American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer

Bruce E. Hillner;James N. Ingle;Rowan T. Chlebowski;Julie Gralow.
Journal of Clinical Oncology (2003)

1232 Citations

Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.

Kathy S. Albain;Valerie W. Rusch;John J. Crowley;Thomas W. Rice.
Journal of Clinical Oncology (1995)

1215 Citations

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard.
The New England Journal of Medicine (2015)

1076 Citations

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.

Kathy S. Albain;John J. Crowley;Michael LeBlanc;Robert B. Livingston.
Journal of Clinical Oncology (1991)

1042 Citations

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

Joseph A. Sparano;Robert J. Gray;Della F. Makower;Kathleen I. Pritchard.
The New England Journal of Medicine (2018)

945 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Kathy S. Albain

David R. Gandara

David R. Gandara

University of California, Davis

Publications: 94

Giuseppe Viale

Giuseppe Viale

European Institute of Oncology

Publications: 78

Eric P. Winer

Eric P. Winer

Harvard University

Publications: 77

Nadia Harbeck

Nadia Harbeck

Ludwig-Maximilians-Universität München

Publications: 71

Frances A. Shepherd

Frances A. Shepherd

Princess Margaret Cancer Centre

Publications: 70

Robert E. Coleman

Robert E. Coleman

University of Sheffield

Publications: 64

Giuseppe Curigliano

Giuseppe Curigliano

European Institute of Oncology

Publications: 62

Everett E. Vokes

Everett E. Vokes

University of Chicago

Publications: 62

Gabriel N. Hortobagyi

Gabriel N. Hortobagyi

The University of Texas MD Anderson Cancer Center

Publications: 61

Mark G. Kris

Mark G. Kris

Memorial Sloan Kettering Cancer Center

Publications: 59

Chandra P. Belani

Chandra P. Belani

Penn State Cancer Institute

Publications: 59

Andreas Schneeweiss

Andreas Schneeweiss

German Cancer Research Center

Publications: 58

Fatima Cardoso

Fatima Cardoso

Champalimaud Foundation

Publications: 56

Jonas Bergh

Jonas Bergh

Karolinska Institutet

Publications: 54

Clifford A. Hudis

Clifford A. Hudis

Memorial Sloan Kettering Cancer Center

Publications: 54

Joseph A. Sparano

Joseph A. Sparano

Albert Einstein College of Medicine

Publications: 54

Something went wrong. Please try again later.